Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

Craig P. Carden, Debashis Sarker, Sophie Postel-Vinay, Timothy A. Yap, Gerthardt Attard, Udai Banerji, Michelle D. Garrett, George V. Thomas, Paul Workman, Stan B. Kaye, Johann S. de Bono

Research output: Contribution to journalReview articlepeer-review

56 Scopus citations

Fingerprint

Dive into the research topics of 'Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds